Invitae Stock

Invitae EV/EBIT

Delisted·Aug 7, 2024

EV/EBIT (Enterprise Value to EBIT) of Invitae (NVTAQ) as of Aug 4, 2026.

EV/EBIT

0.00

YoY

-501.62%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Invitae is 2026 0.00 . EV/EBIT (Enterprise Value to EBIT) of Invitae was 2025 -0.00 . It decreases by -501.62% higher compared to the previous year.

The Invitae EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023
0.00 base
Jan 1, 2024 (e)
0.00 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
0.00 base
YEARPRICE-TO-EBIT
2026 est -
2025 est -
2024 est -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
Access this data via the Eulerpool API
Get Free API Key

Invitae Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Invitae's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Invitae's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Invitae's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Invitae grows earnings faster than its peers.

Invitae Stock analysis

What does Invitae do? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invitae stock

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Invitae since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Invitae with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Invitae

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Invitae